FENNEC PHARMACEUTICALS INC.: 10-Q filed 2013-11-18

Name: FENNEC PHARMACEUTICALS INC.: 10-Q filed 2013-11-18
Creator: FENNEC PHARMACEUTICALS INC.

What FENNEC PHARMACEUTICALS INC. reported in its quarterly report filed 2013-11-18 (fiscal Q3 2013): 22 published measures, 126 facts as tagged in accession 0001144204-13-062582.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-11-18
Fiscal period: fiscal Q3 2013
Accession: 0001144204-13-062582 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All FENNEC PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-09-30	640,000	USD
At 2012-12-31	2,365,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2013-09-30	4,767,000	USD
At 2012-12-31	7,322,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-09-30	-4,127,000	USD
At 2013-06-30	-2,429,000	USD
At 2013-03-31	-9,065,000	USD
At 2012-12-31	-4,957,000	USD
At 2011-12-31	-120,000	USD
At 2010-12-31	-4,926,000	USD
At 2009-12-31	406,000	USD
At 2008-12-31	3,053,000	USD
At 2007-12-31	14,148,000	USD
At 2006-12-31	1,268,000	USD
At 2005-12-31	11,077,000	USD
At 2004-12-31	16,654,000	USD
At 2004-06-30	20,454,000	USD
At 2003-06-30	698,000	USD
At 2002-06-30	6,071,000	USD
At 2001-06-30	9,792,000	USD
At 2000-06-30	47,000	USD
At 1999-06-30	242,000	USD
At 1998-06-30	-435,000	USD
At 1997-06-30	-37,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-09-30	538,000	USD
At 2013-06-30	1,007,000	USD
At 2012-12-31	2,303,000	USD
At 2012-09-30	2,860,000	USD
At 2012-06-30	3,586,000	USD
At 2011-12-31	5,297,000	USD
At 1996-09-02	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	-1,766,000	USD	92
2013-01-01 to 2013-09-30	734,000	USD	273
1996-09-03 to 2013-09-30	-108,400,000	USD	6237
2013-04-01 to 2013-06-30	6,607,000	USD	91
2013-01-01 to 2013-03-31	-4,108,000	USD	90
2012-01-01 to 2012-12-31	-5,163,000	USD	366
2012-07-01 to 2012-09-30	-764,000	USD	92
2012-01-01 to 2012-09-30	1,348,000	USD	274
2011-01-01 to 2011-12-31	4,685,000	USD	365
2010-01-01 to 2010-12-31	-7,824,000	USD	365
2009-01-01 to 2009-12-31	-3,012,000	USD	365
2008-01-01 to 2008-12-31	-13,600,000	USD	366
2007-01-01 to 2007-12-31	-13,357,000	USD	365
2006-01-01 to 2006-12-31	-16,440,000	USD	365
2005-01-01 to 2005-12-31	-13,871,000	USD	365
2004-07-01 to 2004-12-31	-6,594,000	USD	184
2003-07-01 to 2004-06-30	-6,872,000	USD	366
2002-07-01 to 2003-06-30	-17,795,000	USD	365
2001-07-01 to 2002-06-30	-3,732,000	USD	365
2000-07-01 to 2001-06-30	-2,524,000	USD	365
1999-07-01 to 2000-06-30	-1,605,000	USD	366
1998-07-01 to 1999-06-30	-958,000	USD	365
1997-07-01 to 1998-06-30	-398,000	USD	365
1996-09-03 to 1997-06-30	-37,000	USD	301

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	-469,000	USD	92
2013-01-01 to 2013-09-30	-1,765,000	USD	273
1996-09-03 to 2013-09-30	-86,801,000	USD	6237
2012-07-01 to 2012-09-30	-726,000	USD	92
2012-01-01 to 2012-09-30	-2,437,000	USD	274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	0	USD	92
2013-01-01 to 2013-09-30	0	USD	273
1996-09-03 to 2013-09-30	1,440,000	USD	6237
2012-07-01 to 2012-09-30	0	USD	92
2012-01-01 to 2012-09-30	0	USD	274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2013-07-01 to 2013-09-30	USD	92
2013-01-01 to 2013-09-30	USD	273
1996-09-03 to 2013-09-30	USD	6237
2012-07-01 to 2012-09-30	USD	92
2012-01-01 to 2012-09-30	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	0	USD	92
2013-01-01 to 2013-09-30	0	USD	273
1996-09-03 to 2013-09-30	88,445,000	USD	6237
2012-07-01 to 2012-09-30	0	USD	92
2012-01-01 to 2012-09-30	0	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	0	USD	92
2013-01-01 to 2013-09-30	0	USD	273
1996-09-03 to 2013-09-30	-1,483,000	USD	6237
2012-07-01 to 2012-09-30	0	USD	92
2012-01-01 to 2012-09-30	0	USD	274

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	25,158,000	shares	92
2013-01-01 to 2013-09-30	25,158,000	shares	273
2012-07-01 to 2012-09-30	25,158,000	shares	92
2012-01-01 to 2012-09-30	25,158,000	shares	274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	25,158,000	shares	92
2013-01-01 to 2013-09-30	25,648,000	shares	273
2012-07-01 to 2012-09-30	25,158,000	shares	92
2012-01-01 to 2012-09-30	25,158,000	shares	274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	41,000	USD	92
2013-01-01 to 2013-09-30	97,000	USD	273
1996-09-03 to 2013-09-30	10,339,000	USD	6237
2012-07-01 to 2012-09-30	0	USD	92
2012-01-01 to 2012-09-30	17,000	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	-51,000	USD	92
2013-01-01 to 2013-09-30	-1,515,000	USD	273
1996-09-03 to 2013-09-30	-115,760,000	USD	6237
2012-07-01 to 2012-09-30	-630,000	USD	92
2012-01-01 to 2012-09-30	-2,497,000	USD	274

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	0	USD	92
2013-01-01 to 2013-09-30	0	USD	273
1996-09-03 to 2013-09-30	19,000	USD	6237
2012-07-01 to 2012-09-30	0	USD	92
2012-01-01 to 2012-09-30	0	USD	274

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-09-30	315,000	USD
At 2012-12-31	259,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	51,000	USD	92
2013-01-01 to 2013-09-30	1,515,000	USD	273
1996-09-03 to 2013-09-30	115,760,000	USD	6237
2012-07-01 to 2012-09-30	630,000	USD	92
2012-01-01 to 2012-09-30	2,497,000	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-09-30	0	shares
At 2012-12-31	25,158,000	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2013-09-30	1,243,000	USD
At 2012-12-31	1,243,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-09-30	65,000	USD
At 2012-12-31	423,000	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	275,000	USD	92
2013-01-01 to 2013-09-30	1,008,000	USD	273
1996-09-03 to 2013-09-30	33,102,000	USD	6237
2012-07-01 to 2012-09-30	273,000	USD	92
2012-01-01 to 2012-09-30	983,000	USD	274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	-1,715,000	USD	92
2013-01-01 to 2013-09-30	2,249,000	USD	273
1996-09-03 to 2013-09-30	7,360,000	USD	6237
2012-07-01 to 2012-09-30	-134,000	USD	92
2012-01-01 to 2012-09-30	3,845,000	USD	274

Inspect the source

Entity: FENNEC PHARMACEUTICALS INC. / CIK 0001211583
Captured: 2026-09-19T11:17:02.352Z
SEC response SHA-256: f5de26e280e9814def3db187bfe6961cb26c6e601a5f986375859c81818e8ab8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001211583.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))